Novocure Ltd

Company Profile

Novocure Ltd had its IPO on 2015-10-02 under the ticker symbol NVCR.

The company operates in the Healthcare sector and Medical Devices industry. Novocure Ltd has a staff strength of 1,320 employees.

Stock update

Shares of Novocure Ltd opened at $20.24 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $19.38 - $20.28, and closed at $19.95.

This is a -2.64% slip from the previous day's closing price.

A total volume of 1,147,965 shares were traded at the close of the day’s session.

In the last one week, shares of Novocure Ltd have slipped by -10.5%.

Novocure Ltd's Key Ratios

Novocure Ltd has a market cap of $2.14 billion, indicating a price to book ratio of 17.9456 and a price to sales ratio of 14.357.

In the last 12-months Novocure Ltd’s revenue was $507.66 million with a gross profit of $423.58 million and an EBITDA of $-180140000. The EBITDA ratio measures Novocure Ltd's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Novocure Ltd’s operating margin was -37.4% while its return on assets stood at -10.22% with a return of equity of -40.67%.

In Q2, Novocure Ltd’s quarterly earnings growth was a negative -6% while revenue growth was a negative 10.5%.

Novocure Ltd’s PE and PEG Ratio

Forward PE

909.0909

Trailing PE

0

PEG

-0.47

Its diluted EPS in the last 12-months stands at $-1.6 per share while it has a forward price to earnings multiple of 909.0909 and a PEG multiple of -0.47. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Novocure Ltd’s profitability.

Novocure Ltd stock is trading at a EV to sales ratio of 14.01 and a EV to EBITDA ratio of -119.4298. Its price to sales ratio in the trailing 12-months stood at 14.357.

Novocure Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$1.16 billion

Total Liabilities

$150.09 million

Operating Cash Flow

$-13897000.00

Capital Expenditure

$6.93 million

Dividend Payout Ratio

0%

Novocure Ltd ended 2023 with $1.16 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.16 billion while shareholder equity stood at $415.68 million.

Novocure Ltd ended 2023 with $0 in deferred long-term liabilities, $150.09 million in other current liabilities, in common stock, $-888939000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $156.98 million and cash and short-term investments were $940.82 million. The company’s total short-term debt was $67,551,000 while long-term debt stood at $567.15 million.

Novocure Ltd’s total current assets stands at $1.07 billion while long-term investments were $0 and short-term investments were $783.84 million. Its net receivables were $91.14 million compared to accounts payable of $82.54 million and inventory worth $33.02 million.

In 2023, Novocure Ltd's operating cash flow was $-13897000.00 while its capital expenditure stood at $6.93 million.

Comparatively, Novocure Ltd paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$19.95

52-Week High

$120.03

52-Week Low

$18.03

Analyst Target Price

$58.71

Novocure Ltd stock is currently trading at $19.95 per share. It touched a 52-week high of $120.03 and a 52-week low of $120.03. Analysts tracking the stock have a 12-month average target price of $58.71.

Its 50-day moving average was $31.67 and 200-day moving average was $61.73 The short ratio stood at 6.04 indicating a short percent outstanding of 0%.

Around 122% of the company’s stock are held by insiders while 8556.1% are held by institutions.